The Role of Nrf2 Signaling in PPARβ/δ-Mediated Vascular Protection against Hyperglycemia-Induced Oxidative Stress by Jiménez, Rosario et al.
Research Article
The Role of Nrf2 Signaling in PPARβ/δ-Mediated Vascular
Protection against Hyperglycemia-Induced Oxidative Stress
Rosario Jimenez ,1,2,3 Marta Toral,1 Manuel Gómez-Guzmán ,1 Miguel Romero,1,2
Manuel Sanchez,1,2 Ayman M. Mahmoud,4,5,6 and Juan Duarte1,2,3
1Department of Pharmacology, School of Pharmacy, University of Granada, Granada, Spain
2Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain
3Ciber-Enfermedades Cardiovasculares (CIBERCV), Granada, Spain
4Physiology Division, Department of Zoology, Faculty of Science, Beni-Suef University, Beni Suef, Egypt
5Department of Endocrinology, Diabetes and Nutrition, Charité-University Medicine Berlin, Berlin, Germany
6Department of Endocrinology, Diabetes and Nutrition at the Center for Cardiovascular Research (CCR), Charité-University
Medicine Berlin, Berlin, Germany
Correspondence should be addressed to Rosario Jimenez; rjmoleon@ugr.es
Received 23 January 2018; Accepted 18 February 2018; Published 25 June 2018
Academic Editor: Simona Bungau
Copyright © 2018 Rosario Jimenez et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Hyperglycemia induces oxidative stress and plays a substantial role in the progression of vascular diseases. Here, we demonstrated
the potentiality of peroxisome proliferator-activated receptor (PPAR)β/δ activation in attenuating high glucose-induced oxidative
stress in endothelial cells and diabetic rats, pointing to the involvement of nuclear factor erythroid 2-related factor 2 (Nrf2).
HUVECs exposed to high glucose showed increased levels of reactive oxygen species (ROS) and upregulated NOX-2, NOX-4,
Nrf2, and NQO-1 effects that were significantly reversed by the PPARβ/δ agonists GW0742 and L165041. Both PPARβ/δ
agonists, in a concentration-dependent manner, induced transcriptional and protein upregulation of heme oxygenase-1 (HO-1)
under low- and high-glucose conditions. All effects of PPARβ/δ agonists were reversed by either pharmacological inhibition or
siRNA-based downregulation of PPARβ/δ. These in vitro findings were confirmed in diabetic rats treated with GW0742. In
conclusion, PPARβ/δ activation confers vascular protection against hyperglycemia-induced oxidative stress by suppressing
NOX-2 and NOX-4 expression plus a direct induction of HO-1; with the subsequent downregulation of the Nrf2 pathway.
Thus, PPARβ/δ activation could be of interest to prevent the progression of diabetic vascular complications.
1. Introduction
Uncontrolled hyperglycemia in diabetes is linked to many
micro- and macrovascular complications [1]. Several lines
of evidence advocate the role of endothelial dysfunction in
the development of cardiovascular (CV) disease [2]. Endo-
thelial dysfunction (ED) represents the key early step and
the prognostic marker of diabetes-associated vascular com-
plications and is characterized by diminished bioavailability
of vasodilators [3]. In hyperglycemia, oxidative stress and
elevated levels of reactive oxygen species (ROS) in the vessels
are strongly linked to ED [4]. Overproduction of ROS has
been reported to result in a wide account of potentially dam-
aging intermediates that damage DNA, proteins, membrane
structure, and metabolic activity, thereby causing cellular
dysfunction and cell death, which lastly lead to alterations
in the balance between prooxidants and antioxidant arising
several diseases as an outcome [5].
The nuclear factor erythroid 2-related factor 2 (Nrf2) is a
basic leucine zipper protein that suppresses oxidative stress
through activating the transcription of multiple defensive
and antioxidant genes [6]. In the endothelium, Nrf2 has been
reported to be activated via increased ROS generation [7] and
multiple studies have demonstrated the effectiveness of Nrf2
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2 Oxidative Medicine and Cellular Longevity
signaling in counteracting the deleterious repercussion of
ROS in the endothelium [8, 9].
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ)
is a member of a group of nuclear receptors that play diverse
roles in metabolism, development, and cellular differentia-
tion. PPARβ/δ regulates numerous genes implicated in
glucose homeostasis, and fatty acid metabolism is there-
fore ubiquitously expressed in metabolically active tissues
[10, 11]. In high-fat diet- (HFD-) induced type 2 diabetes,
PPARβ/δ activation improves glucose and lipid metabolism
and confers vascular protection [12]. Previous studies have
demonstrated that, independent of their metabolic actions,
PPARβ/δ agonists improved endothelial dysfunction in ani-
mal models of diseases associated with increased ROS, such
as obesity, diabetes, and hypertension [12–16]. In addition,
activation of PPARβ/δ reestablished the altered insulin sig-
naling pathway in human endothelial cells exposed to high
glucose levels [17] and improved vascular reactivity in the
arteries of diabetic rodents [13, 14, 18]. Theses endothelium
protective effects seem to be mediated via inhibition of mito-
chondrial- [17] and nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase-derived ROS production [14] and
ERK1/2 activation [17]. Although PPARβ/δ activation pro-
tects the endothelium against diabetes-associated oxidative
damage by diminishing the sources of ROS in the vascula-
ture, nothing has yet been reported on the role of Nrf2 signal-
ing in mediating the protective effect of PPARβ/δ. Therefore,
we demonstrated the modulatory effect of PPARβ/δ activa-
tion on Nrf2 and its target genes using in vitro high
glucose-induced endothelial cell model and in vivo diabetic
animal model.
2. Materials and Methods
2.1. Cell Culture and Treatments. Human umbilical vein
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Figure 1: Effects of PPARβ/δ agonists on Nrf2 expression. (a, c) mRNA and (b, d) protein expression of Nrf2 in HUVECs exposed to
low (5mM, LG) or high glucose (30mM, HG) for 24 h with or without GW0742 (GW) or L165041 (L) alone or preincubated with
the PPARβ/δ antagonist GSK0660 (GSK). mRNA data presented as a ratio of arbitrary units of mRNA (2−ΔΔCt). All data are mean
± SEM (n = 8), and experiments were repeated at least three times independently. Protein data presented as densitometric values and
protein band normalized to the corresponding α-actin; the bands are representative of n = 3–5. ∗∗P < 0 01 versus LG. #P < 0 05 versus
HG. †P < 0 05 versus L and GW column, respectively.
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previously reported [14] with some adaptations, were used in
all in vitro experiments. The isolated cells were cultured in
medium 199 (M199), and cells from passage 2–5 were used
for the experiments. Following a 2 h serum starvation,
HUVECs were treated with 10−7–10−6M of either GW0742
or L165041 for 24 h in low-glucose (LG; 5mM) or high-
glucose (HG; 30mM) condition. Other HUVECs were prein-
cubated with 10−6M GSK0660, PPARβ/δ antagonist, for 1 h
before treatment with the PPARβ/δ agonists.
2.2. Transfection of PPARβ/δ siRNA. Confluent HUVECs
were transfected with PPARβ/δ or control siRNAs (Dharma-
con, Lafayette, CO, USA) using Lipofectamine RNAiMAX
(Invitrogen, Carlsbad, CA, USA) for 48 h [19]. The efficiency
of PPARβ/δ siRNAs transfection was affirmed using qPCR
and Western blotting.
2.3. Assay of Intracellular ROS. HUVECs were seeded in
96-well plates and treated with PPARβ/δ agonists and/or
antagonist in LG or HG M199 and then incubated with
5μM 2′-7′-dichlorodihydrofluorescein diacetate (CM-
H2DCFDA) at 37
°C for 30min. After washing, the fluores-
cence intensity was determined using a microplate reader
(Fluorostart, BMG Lab Technologies, Offenburg, Germany).
2.4. Gene Expression Analysis. The effect of PPARβ/δ activa-
tion on the expression of Nrf2, NAD(P)H quinone dehydro-
genase 1 (NQO-1), heme oxygenase-1 (HO-1), NOX-4,







































































































Figure 2: Effect of PPARβ/δ agonist, GW0742, on Nrf2 target gene induction. (a, b) mRNA and (c) protein expression of NOQ-1 and HO-1.
HUVECs, exposed to low- (LG) or high-glucose (HG) medium for 24 h, were coincubated with GW0742 (GW) alone or preincubated with
the GSK0660 (GSK) followed by GW0742. mRNA data presented as a ratio of arbitrary units of mRNA (2−ΔΔCt). All data are mean
± SEM (n = 8), and experiments were repeated at least three times independently. Protein data presented as densitometric values and
protein band normalized to the corresponding α-actin; the bands are representative of n = 3–5. ∗P < 0 05 and ∗∗P < 0 01 versus LG.
#P < 0 05 versus HG. +P < 0 05 versus GW column.
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RNA was isolated, quantified, and reverse transcribed into
cDNA. qPCR was performed as we previously reported
[14], using the primers set described in Table 1. The obtained
data were analyzed using the 2−ΔΔCt method with β-actin
or GAPDH as housekeeping genes and normalized to the
control group.
2.5. Western Blot Analysis. Proteins from HUVECs were sep-
arated on SDS-PAGE and transblotted onto PVDF mem-
branes [14, 15]. The blots were probed with antibodies
(Santa Cruz Biotechnology, CA, USA) against Nrf2, NQO-
1, HO-1, and α-actin (Santa Cruz Biotechnology, CA, USA)
followed by the secondary antibody. The ECL system
(Amersham, UK) was used to develop and visualize the blots
which were then analysed using Scion Image-Release Beta
4.02 software (http://scion-image.software.informer.com/).
2.6. Animal Experiments. The effect of PPARβ/δ activation
on Nrf2 signaling in the aorta was investigated using male
Wistar rats weighing 280–320 g and maintained on a 12 h
light/dark cycle at 24± 1°C with standard rat chow water ad
libitum. The experimental protocol was approved by the
institutional review board of the University of Granada
(Spain), and all procedures were conducted according to
the guidelines for the Care and Use of Laboratory Animals
published by National Institutes of Health. Type 1 diabetes
was induced by injection 50mg.kg−1 streptozotocin (STZ)
(Sigma-Aldrich) [14] dissolved in a citrate buffer (pH4.5)
into the tail vein. Three days after intravenous (i.v.) STZ
injection, animals faster for 18 h were screened using an
Accu-Chek Aviva glucometer (Roche Diagnostics S.L., Barce-
lona, Spain) and rats with blood glucose 200mg/dL−1 or










































































































Figure 3: Effect of PPARβ/δ agonist, L165041, on Nrf2 target genes. (a, b) mRNA and (c) protein expression of NOQ-1 and HO-1. HUVECs,
exposed to low- (LG) or high-glucose (HG) medium for 24 h, were coincubated with L165041 (L) alone or preincubated with the GSK0660
(GSK) followed by L165041. mRNA data presented as a ratio of arbitrary units of mRNA (2−ΔΔCt). All data are mean± SEM (n = 8), and
experiments were repeated at least three times independently. Protein data presented as densitometric values and protein band normalized
to the corresponding α-actin; the bands are representative of n = 3–5. ∗P < 0 05 and ∗∗P < 0 01 versus LG. #P < 0 05 and ##P < 0 01 versus
HG. +P < 0 05 versus L column.
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i.v. of citrate buffer. The control and diabetic animals were
divided into 4 groups (N = 8–10) as follows:
Group I (control): rats received the vehicle 1% methylcel-
lulose by gavage for 5 weeks.
Group II (GW-treated): rats received 5mg/kg/day
GW0742 dissolved in 1% methylcellulose [20, 21] by gavage
daily for 5 weeks.
Group III (diabetic): diabetic rats received the vehicle 1%
methylcellulose by gavage for 5 weeks.
Group IV (GW-treated diabetic): diabetic rats received
5mg/kg/day GW0742 dissolved in 1% methylcellulose
[20, 21] by gavage.
At the end of treatments, the rats were sacrificed and dis-
sected and the thoracic aortas were removed. Parts of the
aorta were cut into rings which were cryopreserved in 0.1M
PBS plus 30% sucrose for 1 h, included in OCT medium
and kept frozen −80°C, while other rings were used to assay
NADPH oxidase activity. Other samples of the thoracic aorta
were used to isolate RNA, and the gene expression was deter-
mined as described above.
2.7. In Situ Detection of Vascular Superoxide Anion
Production. The frozen aortic rings were cut into 10μm cross
sections by using a cryostat (Microm International Model
HM 500 OM). The sections were stained with 10μM dihy-
droethidium (DHE) for 30min in the dark at room temper-
ature followed by counterstaining with DAPI. In the
following 24 h, the DHE/DAPI-stained sections were exam-
ined using a fluorescence microscope (Leica DM IRB, Wet-
zlar, Germany) and images were captured. The DHE and
DAPI fluorescence was quantified using ImageJ (version
1.32j, http://imagej-1-32j.updatestar.com/). The relative level
of superoxide was estimated from the DHE/DAPI fluores-
cence ratio [22]. The specificity of the assay was tested using
the superoxide scavenger tiron.
2.8. Assay of NADPH Oxidase Activity. The activity of
NADPH oxidase in thoracic aortic rings of control and dia-
betic rats was assayed by the lucigenin-enhanced chemilumi-
nescence assay as previously described [14]. Briefly, aortic
rings were incubated in HEPES-buffered solution (pH7.4)
to which 100μM NADPH was added. Five μM lucigenin
was added, and the luminescence was recorded at 5 sec inter-
vals over a 200 sec using in a luminometer (Lumat LB 9507,
Berthold, Germany). After subtracting the basal values, the
relative luminescence units (RLU)/min/mg dry tissue was
used to express NADPH oxidase activity.















































































Figure 4: Role of the PPARβ/δ activation on the Nrf2/ARE pathway. mRNA expression levels of (a) Nrf2, (b) NOQ-1, and (c) HO-1 in
control siRNA and siRNA PPARβ/δ cells incubated in low- (LG) or high-glucose (HG) medium for 24 h, in the presence or absence of
GW0742 (GW, 10−6M). mRNA data presented as a ratio of arbitrary units of mRNA (2−ΔΔCt). All data are mean± SEM (n = 8), and
experiments were repeated at least three times independently. ∗P < 0 05 versus LG. #P < 0 01 and ##P < 0 01 versus HG.
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2.9. Statistical Analysis. All data were analyzed using Graph-
Pad Prism 5 (GraphPad Software, San Diego, CA, USA). The
results were expressed as mean± SEM, and comparisons
were made using Student’s t-test or one-way ANOVA
followed by Bonferroni’s post hoc analysis. A P value< 0.05
was considered statistically significant.
3. Results
3.1. High Glucose Increases Nrf2 and Its Target Genes in
HUVECs. HUVECs were incubated in HG medium for
24 h, and the expression of Nrf2, NQO-1, and HO-1 was
assayed. HG induced a significant increase in the expression
of Nrf2 both mRNA and protein (Figure 1). Similarly, the
expression of NQO-1 and HO-1 gene as well as protein was
significantly increased in HUVECs exposed to HG medium
as compared to the LG one as represented in Figures 2
and 3, respectively.
3.2. Effects of PPARβ/δ Agonists on High Glucose-Induced
Changes in Expression of Nrf2 and Its Target Genes.HUVECs
treated with 10−7 and 10−6M GW0742 (Figure 1(a)) or
L165041 (Figure 1(c)) for 24h in LG medium showed non-
significant changes in the expression levels of Nrf2. On the
contrary, coincubation with PPARβ/δ agonists downregu-
lated Nrf2 mRNA (Figures 1(a) and 1(c)) and protein expres-
sion levels (Figures 1(b) and 1(d)) in HG-induced HUVECs.
Coincubation of the HUVECs with 10−6M of the PPARβ/δ
antagonist GSK0660 inhibited the effects exerted by
PPARβ/δ agonists (Figure 1).
The PPARβ/δ agonists did not alter the expression of
NQO-1 mRNA and protein in normal experimental condi-
tions. However, in HUVECs incubated in high-glucose
medium, NQO-1 mRNA and protein levels were decreased
by either GW0742 (Figures 2(a) and 2(c)) or L165041
(Figures 3(a) and 3(c)). Coincubation with GSK0660 mark-
edly abolished the effect of PPARβ/δ agonists on NQO-1
expression, involving PPARβ/δ activation.
In contrast, in both conditions, the incubation with
GW0742 (Figures 2(b) and 2(c)) and L165041 (Figures 3(b)
and 3(c)) upregulated the expression of HO-1 an effect that












































































































Figure 5: Effect of PPARβ/δ agonists in intracellular ROS production. (a) ROS and (b–d) mRNA expression levels of NOX-4 (b), NOX-1 (c),
and NOX-2 (d) in HUVEC transfected with PPARβ/δ-specific siRNA (siRNA PPARβ/δ) incubated in low- (LG) or high-glucose (HG)
medium for 24 h in the presence or absence of either L165041 (L, 10−6M) or GW0742 (GW, 10−6M), respectively. GSK0660 (10−6M) was
added 30min before the incubation with L165041. mRNA data presented as a ratio of arbitrary units of mRNA (2−ΔΔCt). All data are
mean± SEM (n = 8), and experiments were repeated at least three times independently. ∗P < 0 05 versus LG. #P < 0 01 and ##P < 0 01
versus HG.
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PPARβ/δ-induced downregulation of Nrf2 signaling was
confirmed by siRNA-based downregulation of PPARβ/δ.
HUVECs transfected with PPARβ/δ-specific siRNA showed
a marked suppression of GW0742-induced upregulation of
Nrf2 (Figure 4(a)) and NQO-1 (Figure 4(b)) under high-
glucose condition, while the expression of HO-1 was abol-
ished in both conditions (Figure 4(c)).
3.3. Effects of PPARβ/δ Agonists on Intracellular ROS
Production. Oxidative stress induced by hyperglycemia has
been reported in endothelial cells [20]. Accordingly, we
observed higher levels of ROS induced by 30mM of glucose
compared with baseline conditions (5mM glucose)
(Figure 5(a)). The PPARβ/δ agonist L165041 (10−6M) abol-
ished ROS production under the high-glucose condition,
indicating its protective potential at the level of reactive spe-
cies generation. Furthermore, coincubation of this PPARβ/δ
agonist with GSK0660 or PPARβ/δ-specific siRNA sup-
pressed its efficacy to inhibit high glucose-induced ROS
overproduction (Figure 5(a)).
HUVECs, under high-glucose condition, showed
markedly upregulated mRNA abundance of NOX-4
(Figure 5(b)) and NOX-2 (Figure 5(d)) while the expression
of NOX-1 was not significantly affected (Figure 5(c)).
In experimental low-glucose condition, the coincuba-
tion of HUVECs with GW0742 downregulated the mRNA
abundance of NOX-4 (Figure 5(b)); this NOX-4 downreg-
ulation seems to be linked with the capacity to elevate in
both gene and protein expressions of HO-1 expression as
a gene target of PPARβ/δ. Interestingly, the potential of
GW0742 to inhibit the increase of mRNA abundance of
NOX-4 and NOX-2 induced by high glucose was blunted
by the siRNA-mediated downregulation of PPARβ/δ
(Figures 5(b) and 5(d)).
3.4. Effect of GW0742 on Blood Glucose Levels of Control
and Diabetic Rats. STZ diabetic rats showed hyperglycemia
evidenced by the significantly elevated levels of fasting
blood glucose as compared to the control group. In both
experimental groups, the long-term GW0742 administra-
tion did not alter the levels of glucose (Figure 6), indicat-
ing that the protective effect of PPARβ/δ agonist was
glucose-independent.
3.5. Effects of Oral GW0742 on Nrf2 Pathway in Aorta
of Diabetic Rats. Aortas from STZ diabetic rats showed
a marked increase in Nrf2 (Figure 7(a)), NQO-1
(Figure 7(b)), and HO-1 (Figure 7(c)) mRNA expression as
compared to the control rats. Chronic treatment with
GW0742 downregulated Nrf2 and NQO-1 in the aortas of
diabetic rats while it showed no effect on normal rat aorta.
However, similar to the in vitro results, HO-1 mRNA
abundance was higher in the vascular wall of control- and
diabetic-treated rats (Figure 7(c)).
3.6. GW0742 Decreases Vascular ROS and NADPH
Oxidase Activity. To evaluate the effect of GW0742 on
hyperglycemia-provoked oxidative stress, aortic rings from
all experimental groups were stained with DHE and the
activity of NADPH oxidase was determined. DHE staining
revealed increased superoxide levels in the aorta of dia-
betic rats as depicted in Figures 8(a) and 8(b). In the same
context, the aorta of diabetic rats showed significantly
increased activity of NADPH oxidase (Figure 8(c)). While
exerting no effect in normal rats, GW0742 suppressed ROS
levels and NADPH oxidase in the aorta of STZ diabetic rats.
4. Discussion
Oxidative stress is a leading cause of ED and has previ-
ously been implicated in CV complications in diabetes
[4]. Herein, we provide the first evidence that PPARβ/δ
agonists can indirectly downregulate the Nrf2 pathway by
suppressing HG-induced ROS accumulation in the vascu-
lar wall. Given the role of ROS in vascular diseases, our
study suggests a potential therapeutic role of PPARβ/δ in
diabetic vascular complications.
The role of hyperglycemia in diabetes vasculopathy has
been well-acknowledged. Although the vascular endothelium
has adaptive mechanisms to counteract hyperglycemia-
induced oxidative stress, superfluous ROS levels induce
endothelial dysfunction. In endothelial cells, increased super-
oxide generation represents the hallmark of hyperglycemia-
mediated oxidative stress [23]. Accordingly, HUVECs
exposed to HG and aorta of STZ diabetic rats showed mark-
edly elevated levels of ROS. These findings are explained by
the increased activity of NADPH oxidase which represents
a major source of superoxide production under hyperglyce-
mic conditions [17, 24]. Here, HUVECs showed increased
NOX-4 expression following exposure to HG levels. NOX-4
is the prominent and major subunit of NADPH oxidase that
provokes the generation of superoxide anions in the endothe-
lium [25, 26]. Therefore, NOX-4 can induce oxidative dam-









































Figure 6: Effect of GW0742 on blood glucose levels of control and
diabetic rats. Plasma glucose concentrations were measured by
colorimetric method. Values are expressed as mean± SEM of n = 8
–10 rats. ∗∗P < 0 01, diabetic versus control rats.
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stress. Previous studies have also demonstrated increased
NADPH oxidase in diabetic animals [9, 26] and human
patients [29]. In addition, the increased levels of ROS could
be attributed to hyperglycemia-induced eNOS uncoupling
and mitochondrial electron transport chain as previously
demonstrated [30–32]. Interestingly, a functional NOX-4
has been reported to be present in the mitochondria [33].
In a preparation of pure mitochondria, knockdown of
NOX-4 by siRNA blocked mitochondrial superoxide genera-
tion induced by glucose [33]. Moreover, experimental evi-
dence showed that genetic knockdown or inhibition of
NOX-4 reduces ROS production in the vascular endothelium
[27, 34]. Along with the upregulated NOX-4, HG-induced
HUVECs showed increased expression of NOX-2, a NADPH
oxidase subunit known to be expressed in a significant
amount in HUVECs as well as in rat aortic endothelium [26].
GW0742 suppressed NADPH oxidase activity and NOX-
4 induction and prevented oxidative stress, indicating that
the antioxidative action of PPARβ/δ activation was related
to its suppressive effect on NOX-4 activation induced by
HG levels. Since both pharmacological inhibition and knock-
down of PPARβ/δ abolished the suppressive effect of
GW0742 on NOX expression and ROS generation, our
results point to the specific inhibitory role of PPARβ/δ acti-
vation on HG-induced oxidative stress. These findings were
confirmed in vivo where the treatment with GW0742 abol-
ished superoxide generation and reduced NADPH oxidase
in the aorta of STZ diabetic rats. Therefore, the PPARβ/δ-
induced suppression of NOX-4 can significantly improve
the integrity and prevent injury of the vasculature in diabetes.
Accordingly, results from experimental animal models of
STZ- and HFD-induced diabetes treated with GW0742
[12, 14] add support to our findings. Through its ability
to activate PPARβ/δ, GW0742 significantly suppressed
NADPH oxidase activity as well as the expression of its
subunits, p47phox and p22phox, leading to reduced levels
of superoxide in the diabetic aorta [12, 14].
The chronic administration of PPARβ/δ agonist did not
reduce blood glucose levels in STZ diabetic rats, indicating
that its beneficial vascular effects are independent of the
glycemic state. Hence, we investigated the possible role
of Nrf2/ARE/antioxidant signaling. In diabetes, activation
of Nrf2 is an adaptive mechanism that protects the endo-
thelium. This notion is being supported by several in vitro
and in vivo studies. In bovine aortic endothelial cells, acti-
vation of Nrf2 pathway represented a defense mechanism
against oxidative damage induced by advanced glycation
end products [35] and hyperglycemia [32]. Consistent
findings were elucidated by Ungvari et al. [20] in coronary
endothelial cells where the adaptive induction of Nrf2 pro-
tected against the deleterious effects of hyperglycemia. In
Nrf2(+/+) mice, HFD feeding elicited increased expression
of HO-1 mRNA but not in Nrf2(−/−) mice [20]. In addi-
tion, HFD-fed Nrf2(−/−) mice showed increased vascular
ROS levels and diminished vascular reactivity when com-
pared with the Nrf2(+/+) mice received the same HFD,
confirming the role of Nrf2 as an adaptive mechanism to
counteract diabetes-associated endothelial dysfunction
[20]. In our in vitro hyperglycemia model, HUVECs
exhibited upregulated gene and protein expression of
Nrf2 along with increased expression of NQO-1 and
HO-1, adding support to the previous findings. Similarly,
diabetic rats showed upregulated aortic Nrf2, NQO-1,
and HO-1. In conjunction with the activated Nrf2 signal-
ing, the aorta of the diabetic rats exhibited increased
superoxide levels and NADPH oxidase activity. ROS pro-
duced by NOX activity can activate Nrf2 [36, 37] and
hence NOX provides a feedback defense mechanism coun-
teracting oxidative stress [38]. In the same context, Brewer


























































































































































Figure 7: Effect of oral GW0742 on the Nrf2 pathway in the aorta of diabetic rats. mRNA expression of (a) Nrf2, (b) NQO-1, and (c) HO-1 in
the aorta of all experimental groups. Data are presented as the ratio of arbitrary units of mRNA (2−ΔΔCt). Results are shown as mean± SEM
n = 8–10 rats. ∗P < 0 05, diabetic versus control group. #P < 0 05, GW0472-treated diabetic versus nontreated diabetic rats.
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in regulating the redox status in cardiomyocytes in vivo
via activating the Nrf2 pathway.
In our in vitro and in vivo models of hyperglycemia,
PPARβ/δ activation significantly reduced Nrf2 and NQO-1
expression, whereas upregulating HO-1. These results cor-
roborate the findings of Ali et al. [40], who explored the role
of HO-1 in mediating the vasculoprotective efficacy of
PPARβ/δ and its coactivator PGC1α against oxidant-
induced injury. It can thus be suggested that PPARβ/δ ago-
nists induce HO-1 independently of the Nrf2-pathway. HO-
1 has been suggested as a protective factor against vascular
oxidative stress and inflammation [41], and polymorphism
of its gene promotor is associated with vascular diseases















































































































Figure 8: GW0742 decreases vascular ROS and NADPH oxidase activity. (a) The left panel shows blue fluorescence of the nuclear stain DAPI
(×400 magnification), and the right panel shows arteries incubated in the presence of DHE which produces a red fluorescence when oxidized
to ethidium by ROS. (b) Averaged values, mean± SEM (n = 8–10 rings from different rats), of the red ethidium fluorescence normalized
to the blue DAPI fluorescence. (c) NADPH oxidase activity measured by lucigenin-enhanced chemiluminescence (n = 6–10). ∗P < 0 05
and ∗∗P < 0 01, diabetic versus control group. #P < 0 05 and ##P < 0 01, GW0472-treated diabetic versus nontreated diabetic rats.
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1 observed herein contributed to the antioxidant potential of
PPARβ/δ. In addition, the declined activity of NADPH oxi-
dase via PPARβ/δ activation in our experimental models
may be linked to the downregulation of Nrf2 and NQO-1.
GW0742 has exerted a marked effect on the expression
HO-1 as compared to L-165041. This is explained by the fact
that GW0742 is a high-affinity PPARβ/δ agonist while L-
165041 is a nonselective agonist.
In conclusion, this study shows, for the first time, that
PPARβ/δ activation confers vascular protection against oxi-
dative stress in diabetes via direct induction of HO-1 and
downregulation of NOX-4 and, to a lesser extent, NOX-2.
Additionally, the results show that, independent of the glyce-
mic state, activation of PPARβ/δ diminished ROS levels,
NADPH oxidase activity, and expression of Nrf2 and
NQO-1. This research highlights the potential of PPARβ/δ
agonists as novel therapies to reduce vascular complications
of diabetes.
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